Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

CAMBRIDGE, Mass., April 06, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal... | June 20, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,San Diego ,California ,United States ,Matthew Netherton ,Karin Hellsvik ,Hilton Bayfront ,Hans Vitzthum ,Michael Lampe ,Asadm Taherbhoy ,Company Annual Report On Form ,Company Phase ,Twitter ,Exchange Commission ,Nasdaq ,Linkedin ,Foghorn Therapeutics Inc ,Therapeutics Inc ,Annual Drug Discovery Chemistry ,Targeting Transcription Factor ,Drug Discovery ,Selective Heterobifunctional Degrader ,Senior Director ,Medicinal Chemistry ,Gene Traffic ,Annual Report ,Foghorn Therapeutics ,Lifesci Advisors ,